20-12-15 AMAG Pharmaceuticals : Files Submission in Response to the Food and Drug Administration's Notice of Opportunity for a Hearing and Proposal to Withdraw Approval of Makena AQ
20-12-14 AMAG Pharmaceuticals : Files Submission in Response To the Food And Drug Administration’s Notice of Opportunity for a Hearing and Proposal To Withdraw Approval of Makena® (hydroxyprogesterone caproate injection) PU
20-11-17 AMAG PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modifica (form 8-K) AQ
20-11-17 AMAG PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modifica (form 8-K) AQ
20-11-16 AMAG Pharmaceuticals : Covis Group Completes Acquisition of AMAG Pharmaceuticals AQ
Manager TitleAgeSince
President 59 -
Director TitleAgeSince
Director/Board Member 59 -
Director/Board Member - -
Director/Board Member - -
Date Insider Type Main position Quantity % Market Cap. Importance
11/16/20 Issuer sale

Director

131,728 0.3818%
11/16/20 Issuer sale

Chief Financial Officer

41,038 0.1189%
11/16/20 Issuer sale

Chairman

136,253 0.3949%
Change 5-day change 1-year change 3-year change Capi.($)
+0.15%+0.29% - - 477M
+0.83%+3.19%+37.87%+106.25% 1,051B
+1.93%+2.11%+36.82%+64.90% 630B
+1.49%+5.19%+19.84%+85.41% 489B
+2.26%+0.90%+66.40%+39.33% 359B
+1.45%+3.50%+21.87%+42.64% 344B
+1.17%+2.37%+11.71%+35.14% 272B
+0.89%+1.08%-7.28%+10.52% 246B
+1.82%+2.94%+40.43%+52.78% 224B
+2.77%+4.44%+29.49%+101.40% 187B
Average +1.48%+2.53%+28.57%+59.82% 422.63B
Weighted average by Cap. +1.47%+2.44%+31.57%+69.97%
Logo AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals, Inc. is a pharmaceutical company. The Company's segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse. It is engaged in the development of Digoxin immune fab, a polyclonal antibody for the treatment of severe preeclampsia in pregnant women. Makena is a drug indicated to reduce the risk of preterm birth in women pregnant with a single baby having a history of singleton spontaneous preterm birth.
Employees
-
  1. Stock Market
  2. Stocks
  3. AMAG Stock